Jacob Adashek: Tissue is not the issue

Jacob Adashek recently shared a post by the National Cancer Institute (NCI) on Linkedin, adding:

“Tissue is not the issue! Glad to see the National Cancer Institute (NCI) posting our newest treatment summary!”

Quoting the National Cancer Institute (NCI)’s post:

“Precision medicine has rapidly changed the oncology field.

The FDA has approved both gene- and immune-targeted drugs for tissue-agnostic, genomic biomarker-based indications in patients with lethal solid tumors and blood cancers.

The list of drugs approved for tumors with genomic alterations will likely expand as the understanding of the science driving these cancers continues to advance.

Learn more about tissue-agnostic targeted drugs.”

Sources: Jacob Adashek/LinkedIn and National Cancer Institute (NCI)/LinkedIn

Jacob Adashek is a medical oncology fellow at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital.

With a focus on precision medicine, personalized therapies, and first-in-human clinical trials and being interested in biomarker-driven early-phase clinical trials, he has contributed to over 70 peer-reviewed articles in medical journals like Nature Clinical Reviews Oncology and JAMA Oncology. 

He has done clinical research at the City of Hope, specializing in genitourinary oncology, and remains an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.